Home / Health / Sun Pharma Recalls Eye Drops Amid Contamination Fears
Sun Pharma Recalls Eye Drops Amid Contamination Fears
2 Aug
Summary
- Sun Pharma is withdrawing several types of eye drops from the Indian market.
- The recall is a precautionary measure due to suspected contamination concerns.
- Patients are urged to consult doctors for alternative treatments immediately.
Sun Pharma Distributors Ltd has issued a confidential letter to distributors, announcing the withdrawal of several eye drop products, including Depopred, Brinolar, Brinzotim, Lotepred, Nepalact, and Toba-F. This recall, effective immediately as of July 17, is a precautionary measure taken by the company.
The pharmaceutical giant has requested an immediate halt in billing for the affected products and urged distributors to return any existing stock. This action aims to prevent potential patient harm and ensure adherence to safety protocols.
A spokesperson for Sun Pharma stated that patient safety is their highest priority. The company is diligently working to resolve the issue and restore the availability of these essential eye care treatments for patients who rely on them.
Experts warn that interrupting treatment for patients with chronic eye conditions or those recovering from surgery can lead to severe consequences. Maintaining sterility in manufacturing eye drops is paramount, and any suspected contamination necessitates swift recall actions to safeguard public health.
